Inventor

Ira H. Pastan

Inventor

Potomac, MD, US

Overview

1983–2021

Patent span

Human necessities

Primary field (CPC A)

Patents· 121 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary

C07KPeptides29%

A61KPreparations for medical, dental or toiletry purposes27%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations22%

G01NInvestigating or analysing materials by determining their chemical or physical properties8%

C12NMicroorganisms or enzymes5%

Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests5%

A01KAnimal husbandry1%

C12YEnzymes1%

Y02ATechnologies for adaptation to climate change1%

C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms0%

PatentTitleYear

11,065,332Combination therapy of immunotoxin and checkpoint inhibitor2021 10,925,969Anti-BCMA polypeptides and proteins2021 10,703,816M971 chimeric antigen receptors2020 10,683,362Recombinant immunotoxin targeting mesothelin2020 10,494,435Human monoclonal antibodies specific for CD222019 10,428,119None2019 10,111,927Pseudomonas exotoxin A with less immunogenic B cell epitopes2018 10,072,084Dual specific immunotoxin for brain tumor therapy2018 10,072,078M971 chimeric antigen receptors2018 10,053,514Human bispecific EGFRvIII and CD3 antibody engaging molecules2018 10,052,382Methods for using antibodies for 3' iso-LM1 and 3', 6'-iso-LD1tumor gangliosides2018 9,868,774'Anti-CD22 chimeric antigen receptors'2018 9,803,022'Mesothelin domain-specific monoclonal antibodies and use thereof'2017 9,765,123'Pseudomonas exotoxin a with less immunogenic T cell and/or B cell epitopes'2017 9,676,858'Human bispecific EGFRvIII antibody and CD3 engaging molecules'2017 9,657,066'Pseudomonas exotoxin A with less immunogenic B cell epitopes'2017 9,598,492'Human monoclonal antibodies specific for CD22'2017 9,592,304'Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors'2017 9,492,564'Dual specific immunotoxin for brain tumor therapy'2016 9,441,048'Antibody for 3â€²-isoLM1 and 3â€²,6â€²-iso-LD1 gangliosides'2016 9,416,190'Mesothelin antibodies and methods for eliciting potent antitumor activity'2016 9,409,992'Mesothelin domain-specific monoclonal antibodies and use thereof'2016 9,394,352'Immunogenic POTE peptides and methods of use'2016 9,388,222'Modified Pseudomonas exotoxin A'2016 9,359,447'Anti-mesothelin chimeric antigen receptors'2016 9,346,859'Pseudomonas exotoxin A with less immunogenic T cell and/or B cell epitopes'2016 9,279,019'Human monoclonal antibodies specific for CD22'2016 9,249,217'Bispecific EGFRvIII x CD3 antibody engaging molecules'2016 9,206,240'Pseudomonas exotoxin A with less immunogenic B cell epitopes'2015 9,175,057'Immunogenic peptides and methods of use'2015 9,115,196'Antibodies and immunotoxins that target human glycoprotein NMB'2015 8,936,792'Pseudomonas exotoxin a with reduced immunogenicity'2015 8,907,060'Mutated Pseudomonas exotoxins with reduced antigenicity'2014 8,871,906'Deletions in domain II of pseudomonas exotoxin a that remove immunogenic epitopes'2014 8,871,902'Immunogenic POTE peptides and methods of use'2014 8,809,502'Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells'2014 8,748,390'Immunogenic epitopes of NGEP antigen'2014 8,623,828'Blocking mesothelin peptide fragments'2014 8,591,889'Human monoclonal antibodies specific for CD22'2013 8,460,660'Anti-mesothelin antibodies'2013 8,445,216'Antibodies and immunotoxins that target human glycoprotein NMB'2013 8,357,783'Human anti-mesothelin monoclonal antibodies'2013 8,043,623'Immunogenic peptides for the treatment of prostate and breast cancer'2011 8,039,593'Antibodies and immunotoxins that target human glycoprotein NMB'2011 7,999,077'IRTA2 antibodies and methods of use'2011 7,982,011'Mutated anti-cd22 antibodies and immunoconjugates'2011 7,910,692'Immunogenic peptides and methods of use'2011 7,897,355'Gene expressed in prostate cancer and methods of use'2011 7,816,087'Gene expressed in prostate cancer and methods of use'2010 7,777,019'Mutated Anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells'2010 7,709,252'Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use'2010 7,572,887'Gene expressed in prostate cancer, methods and use thereof'2009 7,541,035'Immunogenic peptides for the treatment of prostate and breast cancer'2009 7,541,034'Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors'2009 7,521,054'Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the Fv to lower the isoelectric point'2009 7,470,775'Anti-CD30 stalk and anti-CD30 antibodies suitable for use in immunotoxins'2008 7,410,801'Lambda phage display system and the process'2008 7,399,827'Page-4, an x-linked gage-like gene expressed in normal and neoplastic prostate, testis and uterus, and uses therefor'2008 7,375,183'Mesothelin, immunogenic peptides derived therefrom, and compositions comprising mesothelin, or immunogenic peptides thereof'2008 7,368,110'Antibodies, including Fv molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use'2008 7,355,012'Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells'2008 7,129,332'Anti-EGFRvIII scFvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof'2006 7,081,518'Anti-mesothelin antibodies having high binding affinity'2006 7,052,703'T-cell receptorÎ³ alternate reading frame protein, (TARP) and uses thereof'2006 6,809,184'Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use'2004 6,558,672'Methods of making recombinant disulfide-stabilized polypeptide fragments having binding specificity'2003 6,518,061'IL-13 receptor specific chimeric proteins and uses thereof'2003 6,426,075'Protease-activatable pseudomonas exotoxin A-like proproteins'2002 6,423,513'Polynucleotides encoding protease-activatable pseudomonas exotoxin a-like proproteins'2002 6,287,562'Methods of inhibiting the growth of cells bearing LewisY antigens using B1, B3, or B5 targeted immunoconjugates'2001 6,232,086'Method for detecting cancer cells'2001 6,156,564'Cellular apoptosis susceptibility protein (CSP) and antisense CSP'2000 6,153,430'Nucleic acid encoding mesothelin, a differentiation antigen present on mesothelium, mesotheliomas and ovarian cancers'2000 6,147,203'Recombinant disulfide-stabilized polypeptide fragments having binding specificity'2000 6,099,842'Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin'2000 6,083,502'Mesothelium antigen and methods and kits for targeting it'2000 6,074,644'Nucleic acids encoding immunotoxins containing a disulfide-stabilized antibody fragment replacing half or more of domain IB of pseudomonas exotoxin, and methods of use of the encoded immunotoxins'2000 6,072,031'Cellular apoptosis susceptibility protein (CSP)'2000 6,051,405'Constructs encoding recombinant antibody-toxin fusion proteins'2000 6,011,002'Circularly permuted ligands and circularly permuted chimeric molecules'2000 5,990,296'Single chain B3 antibody fusion proteins and their uses'1999 5,980,895'Immunotoxin containing a disulfide-stabilized antibody fragment joined to a Pseudomonas exotoxin that does not require proteolytic activation'1999 5,981,726'Chimeric and mutationally stabilized tumor-specific B1, B3 and B5 antibody fragments; immunotoxic fusion proteins; and uses thereof'1999 5,928,637'Methods of inducing multidrug resistance using human MDR1 cDNA'1999 5,919,456'IL-13 receptor specific chimeric proteins'1999 5,889,157'Humanized B3 antibody fragments, fusion proteins, and uses thereof'1999 5,863,745'Recombinant antibody-toxin fusion protein'1999 5,854,044'Recombinant pseudomonas exotoxin with increased activity'1998 5,851,819'Vectors carrying MDR1 cDNA which confer multidrug resistance on transduced cells'1998 5,849,998'Transgenic animals expressing a multidrug resistance cDNA'1998 5,846,535'Methods for reducing tumor cell growth by using antibodies with broad tumor reactivity and limited normal tissue reactivity'1998 5,821,238'Recombinant pseudomonas exotoxin with increased activity'1998 5,817,313'Monoclonal antibodies and conjugates thereof useful for the treatment of cancer'1998 5,759,782'Cellular apoptosis susceptibility protein (CSP) and antisense CSP'1998 5,747,654'Recombinant disulfide-stabilized polypeptide fragments having binding specificity'1998 5,705,156'Psuedomonas exotoxins of low animal toxicity and high cytocidal activity'1998 5,705,163'Target-specific, cytotoxic, recombinant pseudomonas exotoxin'1998 5,696,237'Recombinant antibody-toxin fusion protein'1997 5,635,599'Fusion proteins comprising circularly permuted ligands'1997 5,614,191'IL-13 receptor specific chimeric proteins and uses thereof'1997 5,612,032'Method for diagnosing tumors using mouse monoclonal antibodies'1997 5,608,039'Single chain B3 antibody fusion proteins and their uses'1997 5,602,095'Recombinant pseudomonas exotoxin with increased activity'1997 5,587,455'Cytotoxic agent against specific virus infection'1996 5,525,337'Monoclonal antibody binding cell surface antigens for diagnosing cancer'1996 5,512,658'Pseudomonas exotoxins (PE) and conjugates thereof having lower animal toxicity with high cytocidal activity through substitution of positively charged amino acids'1996 5,489,525'Monoclonal antibodies to prostate cells'1996 5,458,878'P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity'1995 5,428,143'Cytotoxic agent against specific virus infection'1995 5,328,984'Recombinant chimeric proteins deliverable across cellular membranes into cytosol of target cells'1994 5,320,956'Monoclonal antibody useful for the diagnosis of cancer'1994 5,242,813'Mouse monoclonal antibodies specific for normal primate tissue, malignant human cultural cell lines human tumors'1993 5,206,352'Compositions for clones containing DNA sequences associated with multidrug resistance in human cells'1993 5,206,353'CD-4/cytotoxic gene fusions'1993 5,166,059'Gene therapy using gene fusions for genetic or acquired disorders'1992 5,082,927'Selectively cytotoxic IL-4-PE40 fusion protein'1992 4,958,009'Anti-human ovarian cancer immunotoxins and methods of use thereof'1990 4,892,827'Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects'1990 4,806,494'Monoclonal antibody against ovarian cancer cells (OVB-3)'1989 4,545,985'Pseudomonas exotoxin conjugate immunotoxins'1985 4,396,628'Antiviral activities of dansylcadaverine and closely related compounds'1983

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1983–2021Based in Potomac, MD, US· patent location history

1985–2021Patents assigned to US HEALTH (97)· patent assignee history

2008Based in Potamac, MD, US· patent location history

2011–2021Patents assigned to UNIV DUKE (11)· patent assignee history

2013–2020Patents assigned to PASTAN IRA H (13)· patent assignee history

2013–2017Patents assigned to PASTAN IRA (5)· patent assignee history

2014–2020Patents assigned to BEERS RICHARD (4)· patent assignee history

2014Based in Bethesda, MD, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
US HEALTH	97	1985–2021
PASTAN IRA Hself	13	2013–2020
UNIV DUKE	11	2011–2021
PASTAN IRAself	5	2013–2017
BEERS RICHARD	4	2014–2020

Locations

Location	Patents	Span
Potomac, Maryland, US	118	1983–2021
Bethesda, Maryland, US	2	2014
Potamac, Maryland, US	1	2008